Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Memantine Treatment Report
What is Memantine?

Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system. It is also being tested for use as a cognitive enhancer in a variety of other conditions. Read more...Click to read more below

Merz's Memantine site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell 		# of patients evaluated by
ALS Amyotrophic lateral sclerosis 15 1
Emotional lability 2 0
Stiffness/Spasticity 1 0
Other 1 0

See all 11 patients currently taking Memantine

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
1 100%

Dosages

  20 mg weekly 10 mg daily 15 mg daily 20 mg daily 40 mg daily 100 mg daily
  1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Memantine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
7 88% Did not seem to work: 88%
Expense
1 13% Expense: 13%
Side effects too severe
1 13% Side effects too severe: 13%
Other
1 13% Other: 13%

See all 8 patients who’ve stopped taking Memantine

Duration See details about how long patients take this treatment ▼

Currently Taking Memantine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Memantine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 100%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 100%
< $25
0 0%

Report created on March 19, 2010.